Administration of a sterile injectable that has foreign particulates has the potential of severe health consequences.
Injected particulate may result in local inflammation, low-level allergic or immune responses, granuloma formation or mechanical irritation of tissue.
The results obtained from these test kits have not been demonstrated to be accurate and should not be used as diagnostic tests for Ebola infection. Posted 04/23/2015
Consumers could take a product with undeclared levels of acetaminophen, dextromethorphan, guaifenesin, phenylephrine and/or diphenhydramine.
Evidence of NSAID toxicity in the pets exposed to flurbiprofen and died.
Separation could result in required intervention to prevent permanent impairment or damage.
Particles in IV solutions may cause: local vein irritation, inflammatory reaction, aggravation of preexisting infections, allergic reactions, and systemic embolization.
UPDATED 04/08/2015. Wallcur Practi-IV solutions bags are recalled.
Human and veterinary drug products made by the Prescription Center have been distributed nationwide and to Canada.
Risk of potentially life-threatening allergic reactions.
If not properly reprocessed patients may be exposed to serious infections.
The facility may not perform mammography due to the revocation of its accreditation.
Postmarketing cases of serious and life-threatening symptomatic bradycardia, as well as one fatal cardiac arrest and cases requiring pacemaker insertion, have been reported.
FDA is unable to exclude the possibility that the deaths were caused by rapid, but delayed, entry of the drug into the bloodstream following intramuscular injection.
If asthma is not appropriately treated and managed, patients may be at risk for life-threatening asthma attacks.